Meeting Banner
Abstract #1864

Rapid estimation of myelin for diagnostic imaging (REMyDI): A clinical and histopathological validation in multiple sclerosis

Russell Ouellette1,2,3,4, Marcel Warntjes5,6, Yngve Forslin1,2, Michael Plattén1,2, Martin Uppman1, Åsa Bergendal1,7, Fredrik Piehl1,8, Sten Fredrikson1,8, Maria Kristoffersen-Wiberg1,2, Caterina Mainero3,4, and Tobias Granberg1,2,3,4

1Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 2Department of Radiology, Division of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden, 3Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, United States, 4Harvard Medical School, Boston, MA, United States, 5Synthetic MR, Stockholm, Sweden, 6Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden, 7Department of Medical Psychology, Karolinska University Hospital, Stockholm, Sweden, 8Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

Multiple sclerosis is a chronic inflammatory and neurodegenerative disease characterized by demyelination. To follow patients longitudinally and monitor treatment response, there is a need for robust and tissue-specific imaging biomarkers reflective of the heterogeneous disease course. Here, we aimed to validate REMyDI as an MRI-based measure of myelin ex vivo and in vivo. Histopathologically, REMyDI correlates well with all three of the studied myelin staining methods. In vivo, REMyDI revealed a strong sensitivity in differentiating white matter as compared to normal appearing white matter with associations to both cognitive (information processing speed) and physical disability (Expanded Disability Status Scale).

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract